Humanwell Healthcare Group Co Ltd (SHG:600079) — Market Cap & Net Worth

$4.47 Billion USD  · CN¥30.57 Billion CNY  · Rank #3861

Market Cap & Net Worth: Humanwell Healthcare Group Co Ltd (600079)

Humanwell Healthcare Group Co Ltd (SHG:600079) has a market capitalization of $4.47 Billion (CN¥30.57 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #3861 globally and #559 in its home market, demonstrating a 1.02% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Humanwell Healthcare Group Co Ltd's stock price CN¥18.73 by its total outstanding shares 1632225965 (1.63 Billion). Also see 600079 current and non-current assets for a full breakdown of the balance sheet.

Humanwell Healthcare Group Co Ltd Market Cap History: 2015 to 2026

Humanwell Healthcare Group Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $5.09 Billion to $4.47 Billion (0.46% CAGR). Also see 600079 cash flow conversion for how efficiently the company converts equity into cash flow.

Humanwell Healthcare Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Humanwell Healthcare Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Humanwell Healthcare Group Co Ltd stock quote for real-time trading data and today's change.

Latest Price to Sales (P/S) Ratio

0.18x

Humanwell Healthcare Group Co Ltd's market cap is 0.18 times its annual revenue

Industry average: 0.64x Lower than industry average

Latest Price to Earnings (P/E) Ratio

2.33x

Humanwell Healthcare Group Co Ltd's market cap is 2.33 times its annual earnings

Industry average: 5.48x Lower than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $4.59 Billion $12.33 Billion $832.40 Million 0.37x 5.51x
2017 $4.12 Billion $15.45 Billion $2.07 Billion 0.27x 1.99x
2018 $2.37 Billion $18.63 Billion -$2.36 Billion 0.13x N/A
2019 $3.16 Billion $21.81 Billion $842.54 Million 0.15x 3.75x
2020 $7.94 Billion $20.68 Billion $1.01 Billion 0.38x 7.90x
2021 $5.30 Billion $20.55 Billion $1.32 Billion 0.26x 4.03x
2022 $5.67 Billion $22.34 Billion $2.48 Billion 0.25x 2.28x
2023 $5.94 Billion $24.52 Billion $2.13 Billion 0.24x 2.78x
2024 $5.58 Billion $25.44 Billion $1.33 Billion 0.22x 4.20x
2025 $4.33 Billion $23.96 Billion $1.86 Billion 0.18x 2.33x

Competitor Companies of 600079 by Market Capitalization

Companies near Humanwell Healthcare Group Co Ltd in the global market cap rankings as of September 24, 2026. Review Humanwell Healthcare Group Co Ltd (600079) tangible net worth to assess the quality of the company's equity after excluding intangible assets.

Key companies related to Humanwell Healthcare Group Co Ltd by market ranking:

  • Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
  • GALDERMA GROUP AG (NYSE:GALDY): Ranked #586 globally with a market cap of $46.44 Billion USD.
  • Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #638 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
  • Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #651 globally with a market cap of $42.68 Billion USD ( CN¥291.65 Billion CNY).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#524 Takeda Pharmaceutical Co Ltd ADR NYSE:TAK $52.60 Billion $16.65
#586 GALDERMA GROUP AG NYSE:GALDY $46.44 Billion $39.83
#638 Takeda Pharmaceutical Company Limited F:TKDA $43.60 Billion €16.50
#651 Jiangsu Hengrui Medicine Co Ltd SHG:600276 $42.68 Billion CN¥45.72

Humanwell Healthcare Group Co Ltd Historical Marketcap From 2015 to 2026

Between 2015 and today, Humanwell Healthcare Group Co Ltd's market cap moved from $5.09 Billion to $ 4.47 Billion, with a yearly change of 0.46%.

Year Market Cap Change (%)
2026 CN¥4.47 Billion +3.42%
2025 CN¥4.33 Billion -22.54%
2024 CN¥5.58 Billion -5.95%
2023 CN¥5.94 Billion +4.71%
2022 CN¥5.67 Billion +6.94%
2021 CN¥5.30 Billion -33.25%
2020 CN¥7.94 Billion +151.17%
2019 CN¥3.16 Billion +33.23%
2018 CN¥2.37 Billion -42.44%
2017 CN¥4.12 Billion -10.06%
2016 CN¥4.59 Billion -9.87%
2015 CN¥5.09 Billion --

End of Day Market Cap According to Different Sources

On Sep 23rd, 2026 the market cap of Humanwell Healthcare Group Co Ltd was reported to be:

Source Market Cap
Yahoo Finance $4.47 Billion USD
MoneyControl $4.47 Billion USD
MarketWatch $4.47 Billion USD
marketcap.company $4.47 Billion USD
Reuters $4.47 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Humanwell Healthcare Group Co Ltd

SHG:600079 China Drug Manufacturers - Specialty & Generic
Market Cap
$4.47 Billion
CN¥30.57 Billion CNY
Market Cap Rank
#3861 Global
#559 in China
Share Price
CN¥18.73
Change (1 day)
-0.27%
52-Week Range
CN¥16.37 - CN¥21.54
All Time High
CN¥37.30
About

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for pa… Read more